Amgen Australia Pty Ltd
Regulatory activities for this sponsor.
Loading...
Sponsor content
167 result(s) found, displaying 11 to 20
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for GANVADO denosumab (rch) 70mg/mL (120mg/1.7mL) solution for injection vial.
-
Australian Public Assessment Report (AusPAR)Kyprolis (carfilzomib) was approved to treat relapsed or refractory multiple myeloma.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AJEMNYE ustekinumab 45 mg / 0.5 mL solution for subcutaneous injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AJEMNYE ustekinumab 90 mg/1.0 ml solution for subcutaneous injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AJEMNYE ustekinumab 5 mg / 1.0 mL (130 mg/26 mL) solution for intravenous infusion injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AJEMNYE ustekinumab 45 mg / 0.5 mL solution for subcutaneous injection pre-filled syringe.
-
Jul-2024Prescription medicine evaluationActive ingredient: tarlatamab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for WEZLANA ustekinumab 90 mg/1.0 ml solution for subcutaneous injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for WEZLANA ustekinumab 45 mg / 0.5 mL solution for subcutaneous injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for WEZLANA ustekinumab 5 mg / 1.0 mL (130 mg/26 mL) solution for intravenous infusion injection vial.